Scarica l'app Stockscreener
26.24
1.70%
0.40
Precedente Chiudi:
$25.84
Aprire:
$25.93
Volume 24 ore:
195.31K
Relative Volume:
0.22
Capitalizzazione di mercato:
$1.22B
Reddito:
$681.75M
Utile/perdita netta:
$70.47M
Rapporto P/E:
18.10
EPS:
1.45
Flusso di cassa netto:
$173.19M
1 W Prestazione:
+2.06%
1M Prestazione:
-0.64%
6M Prestazione:
+47.56%
1 anno Prestazione:
-13.35%
Intervallo 1D:
$25.36
$26.43
Intervallo di 1 settimana:
$25.33
$26.44
Portata 52W:
$11.16
$31.64
Pacira Biosciences Inc Stock (PCRX) Company Profile
Nome
Pacira Biosciences Inc
Settore
Telefono
650-242-8052
Indirizzo
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Confronta PCRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
26.24 | 1.20B | 681.75M | 70.47M | 173.19M | 1.45 |
|
HLN
Haleon Plc Adr
|
11.35 | 50.54B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
168.21 | 74.02B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.78 | 4.22M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.98 | 45.82B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.96 | 20.31B | 16.54B | -1.64B | 749.00M | -1.45 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-30 | Aggiornamento | Truist | Sell → Hold |
| 2024-08-13 | Downgrade | Truist | Buy → Sell |
| 2024-08-12 | Downgrade | JP Morgan | Overweight → Underweight |
| 2024-08-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-03-07 | Ripresa | JP Morgan | Overweight |
| 2023-12-20 | Iniziato | Raymond James | Outperform |
| 2023-08-03 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | Ripresa | Wedbush | Outperform |
| 2022-10-21 | Ripresa | Jefferies | Buy |
| 2022-01-03 | Ripresa | JP Morgan | Overweight |
| 2021-07-26 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-04-21 | Ripresa | JP Morgan | Neutral |
| 2021-04-09 | Iniziato | Berenberg | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-02-11 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | Reiterato | Needham | Buy |
| 2020-05-27 | Iniziato | Guggenheim | Neutral |
| 2020-04-07 | Iniziato | Northland Capital | Outperform |
| 2020-03-20 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-24 | Iniziato | SunTrust | Buy |
| 2020-01-23 | Iniziato | SunTrust | Buy |
| 2019-11-06 | Iniziato | BTIG Research | Buy |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-05-06 | Aggiornamento | Mizuho | Underperform → Neutral |
| 2019-05-02 | Aggiornamento | Stifel | Sell → Hold |
| 2019-02-01 | Downgrade | Mizuho | Neutral → Underperform |
| 2018-08-06 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | Reiterato | H.C. Wainwright | Buy |
| 2018-03-21 | Reiterato | Mizuho | Neutral |
| 2018-02-16 | Downgrade | Needham | Buy → Hold |
| 2018-01-19 | Iniziato | Seaport Global Securities | Buy |
| 2018-01-04 | Reiterato | Canaccord Genuity | Buy |
| 2018-01-03 | Iniziato | Leerink Partners | Mkt Perform |
Mostra tutto
Pacira Biosciences Inc Borsa (PCRX) Ultime notizie
Two Sigma Investments LP Purchases 45,222 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Q3 EPS Estimate for Pacira BioSciences Raised by Analyst - Defense World
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Acquired by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Purchased by ProShare Advisors LLC - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Pacira BioSciences’s First Quarter 2025 Misses Estimates - Orthopedics This Week
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Purchased by Nuveen Asset Management LLC - Defense World
Grabar Law Office Investigates Claims on Behalf of - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Reach Out - ACCESS Newswire
Trading (PCRX) With Integrated Risk Controls - news.stocktradersdaily.com
Ameriprise Financial Inc. Acquires 194,597 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Average Recommendation of “Hold” from Brokerages - Defense World
Pacira BioSciences (NASDAQ:PCRX) adds US$78m to market cap in the past 7 days, though investors from three years ago are still down 57% - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
2025-05-18 | Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Shareholders to Inquire about Securities Investigation | Press Release - Stockhouse
The Manufacturers Life Insurance Company Sells 458 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by Comerica Bank - Defense World
Northern Trust Corp Buys 145,205 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit - GuruFocus
Pacira (PCRX) Reports Promising Data on PCRX-201 Gene Therapy fo - GuruFocus
Pacira (PCRX) Reports Promising Data on PCRX-201 Gene Therapy for Knee Osteoarthritis | PCRX Stock News - GuruFocus
Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee - The Manila Times
Pacira BioSciences Presents New Data on the Effects of - GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences - GlobeNewswire
Pacira Biosciences announces $300M share repurchase program - MSN
(PCRX) Trading Report - news.stocktradersdaily.com
Lawsuit for Investors in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) announced by the Shareholders Foundation - PR Newswire
2025-05-13 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRA) And Encourages Shareholders to Reach Out | Press Release - Stockhouse
Raymond James Financial Inc. Invests $190,000 in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by Tower Research Capital LLC TRC - Defense World
Needham & Company LLC Cuts Pacira BioSciences (NASDAQ:PCRX) Price Target to $30.00 - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Shareholders of Pacira BioSciences, Inc. Should Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your RightsPCRX - ACCESS Newswire
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2025 Earnings Call Transcript - Insider Monkey
Pacira BioSciences (NASDAQ:PCRX) Shares Gap Down on Analyst Downgrade - Defense World
Pacira BioSciences (PCRX) Stock Rating Maintained but Price Targ - GuruFocus
Levi & Korsinsky Reminds Pacira BioSciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025PCRX - ACCESS Newswire
Pacira outlines growth potential with $725M-$765M 2025 revenue target and EXPAREL expansion to 2039 - MSN
Earnings call transcript: Pacira Q1 2025 shows revenue miss, stock dips - Investing.com Australia
Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates - Nasdaq
Pacira BioSciences (PCRX) Stock Rating Maintained but Price Target Lowered | PCRX Stock News - GuruFocus
Where Pacira BioSciences Stands With Analysts - Benzinga
Pacira BioSciences Q1 2025 Earnings Call Transcript - MarketBeat
Pacira Q1 Adjusted Earnings Unchanged; Revenue Rises; 2025 Sales Guidance Steady - marketscreener.com
Pacira BioSciences Inc (PCRX) Q1 2025 Earnings Call Highlights: Strong EXPAREL Sales and ... - Yahoo Finance
Decoding Pacira BioSciences Inc (PCRX): A Strategic SWOT Insight - GuruFocus
Pacira BioSciences Reports Q1 2025 Financial Results - TipRanks
Pacer Advisors, Inc. Significantly Reduces Holdings in Pacira Bi - GuruFocus
Pacer Advisors, Inc. Reduces Stake in Pacira BioSciences Inc - GuruFocus
Pacira BioSciences Reports First Quarter 2025 Financial Results - GlobeNewswire
Pacira Biosciences Inc Azioni (PCRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Pacira Biosciences Inc Azioni (PCRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| SLONIN JONATHAN | Chief Medical Officer |
Jan 06 '25 |
Sale |
18.40 |
879 |
16,174 |
93,444 |
3.31%
0.59%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):